
NASDAQHealthcareMedical - Instruments & Supplies
أحدث البيانات المتاحة
21.67 US$
−0.71 US$ · -3.17%
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
أحدث البيانات المتاحة
21.67 US$
−0.71 US$ · -3.17%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
49
قيمة عادلة
المشاعر
68
صعودي
المخاطر
51
مخاطر أعلى من المعتاد
الزخم
46
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
STAAR Surgical Company, along with its subsidiaries, specializes in ophthalmological solutions, focusing on the design, development, manufacturing, and commercialization of implantable lenses for vision correction, complete with the sophisticated delivery systems necessary for their implantation. A core offering is the Visian implantable Collamer lens (ICL) product line, designed to correct various visual impairments including myopia (nearsightedness), hyperopia (farsightedness), astigmatism, and presbyopia (age-related loss of near vision). Specifically, their Hyperopic ICL addresses farsightedness. Furthermore, STAAR Surgical provides preloaded silicone intraocular lenses and associated injector systems, crucial for cataract surgery. The company also sells various injector components and ancillary medical instruments and devices. Its market outreach extends to a diverse array of healthcare providers, such as ophthalmic surgeons, specialized vision and surgical centers, hospitals, governmental healthcare facilities, and distributors. These products are predominantly utilized by ophthalmologists. Sales are conducted directly via its own sales force in key countries like the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore. In other significant markets, including China, Korea, India, France, the Benelux region, Italy, and other international territories, the company employs a hybrid sales model, leveraging both its direct representatives and independent distributors. Founded in 1982, STAAR Surgical Company is headquartered in Lake Forest, California.
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 239.44 مليون USD | 313.9 مليون USD | 322.42 مليون USD | 284.39 مليون USD | 230.47 مليون USD |
| تكلفة البضاعة المباعة | 57.02 مليون USD | 74.32 مليون USD | 69.76 مليون USD | 61.01 مليون USD | 51.84 مليون USD |
| الربح الإجمالي | 182.42 مليون USD | 239.58 مليون USD | 252.65 مليون USD | 223.38 مليون USD | 178.64 مليون USD |
| البحث والتطوير | 40.06 مليون USD | 53.97 مليون USD | 44.4 مليون USD | 35.98 مليون USD | 33.86 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 188.31 مليون USD | 198.22 مليون USD | 180.15 مليون USD | 143.6 مليون USD | 111.44 مليون USD |
| نفقات التشغيل | 228.37 مليون USD | 252.19 مليون USD | 224.55 مليون USD | 179.58 مليون USD | 145.3 مليون USD |
| دخل الفوائد | 4.59 مليون USD | 5.91 مليون USD | 6.99 مليون USD | 2.45 مليون USD | — |
| مصاريف الفوائد | — | — | — | — | 38 ألف USD |
| الاستهلاك والإطفاء | 8.32 مليون USD | 6.89 مليون USD | 5.12 مليون USD | 4.51 مليون USD | 3.64 مليون USD |
| الدخل التشغيلي | −45.95 مليون USD | −12.61 مليون USD | 28.1 مليون USD | 43.8 مليون USD | 33.34 مليون USD |
| صافي الدخل | −80.45 مليون USD | −20.21 مليون USD | 21.35 مليون USD | 39.67 مليون USD | 27.51 مليون USD |
تم تحديث حقائق الشركة 10 أكتوبر 2026.
أحدث النتائج المعلنة
أحدث النتائج المعلنة
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
| الإجراء | تاريخ النفاذ | تفاصيل | تاريخ التسجيل | تاريخ الدفع |
|---|---|---|---|---|
تقسيم الأسهم | 18 مايو 1992 | 1:2 | — | — |
تقسيم الأسهم | 1 نوفمبر 1990 | 1:2 | — | — |
تقسيم الأسهم | 9 نوفمبر 1984 | 2:1 | — | — |
تقسيم الأسهم | 3 يوليو 1984 | 2:1 | — | — |
ساري 18 مايو 1992
1:2
ساري 1 نوفمبر 1990
1:2
ساري 9 نوفمبر 1984
2:1
ساري 3 يوليو 1984
2:1
صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI21.45 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
iShares Russell 2000 ETFIWM17.99 مليون0.02%78.27 مليار USD0.19%278.94 US$+0.49%
Vanguard Morningstar Small-Cap ETFVB15.51 مليون0.01%185.3 مليار USD0.03%289.48 US$+0.64%
Vanguard Extended Market ETFVXF13.03 مليون0.01%95.4 مليار USD0.05%235 US$+0.80%
Vanguard Morningstar Small-Cap Growth ETFVBK8.86 مليون0.02%44.7 مليار USD0.05%344.74 US$+1.22%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM6.21 مليون0.04%15.84 مليار USD0.03%53.45 US$+0.17%
Dimensional - US Small Cap ETFDFAS5.95 مليون0.02%33.87 مليار USD0.31%78.35 US$+0.32%
iShares Russell 2000 Growth ETFIWO5.69 مليون0.04%13.97 مليار USD0.24%356.78 US$+0.94%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Small-Cap ETFVB
Vanguard Extended Market ETFVXF
Vanguard Morningstar Small-Cap Growth ETFVBK
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Dimensional - US Small Cap ETFDFAS
iShares Russell 2000 Growth ETFIWOالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.